Quarterly report pursuant to Section 13 or 15(d)

SEGMENT REPORTING (Details) - Schedule of Segment Reporting Information, by Segment

v3.20.2
SEGMENT REPORTING (Details) - Schedule of Segment Reporting Information, by Segment - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Segment Reporting Information [Line Items]        
Research and development $ 4,910,827 $ 1,643,659 $ 15,555,725 $ 4,950,457
General and administrative 8,165,488 3,841,189 32,628,919 14,380,898
Depreciation and amortization 23,869   67,092  
Total operating expenses 13,100,184 5,503,358 48,251,736 19,367,779
Loss from Operations (13,100,184)   (48,251,736)  
Interest income and other income, net 1,743   43,612  
Net loss (13,098,441) $ (5,464,004) (48,208,124) $ (19,283,156)
Corporate Segment [Member]        
Segment Reporting Information [Line Items]        
Research and development 698,310   3,112,294  
General and administrative 6,807,422   18,755,512  
Depreciation and amortization 23,012   66,235  
Total operating expenses 7,528,744   21,934,041  
Loss from Operations (7,528,744)   (21,934,041)  
Interest income and other income, net 1,453   28,915  
Net loss (7,527,291)   (21,905,126)  
ViralClear [Member]        
Segment Reporting Information [Line Items]        
Research and development 4,182,887   12,413,801  
General and administrative 1,357,805   13,873,146  
Depreciation and amortization 0   0  
Total operating expenses 5,540,692   26,286,947  
Loss from Operations (5,540,692)   (26,286,947)  
Interest income and other income, net 290   14,697  
Net loss (5,540,402)   (26,272,250)  
NeuroClear Technologies, Inc ("NeuroClear") [Member]        
Segment Reporting Information [Line Items]        
Research and development 29,630   29,630  
General and administrative 261   261  
Depreciation and amortization 857   857  
Total operating expenses 30,748   30,748  
Loss from Operations (30,748)   (30,748)  
Interest income and other income, net 0   0  
Net loss $ (30,748)   $ (30,748)